EMA panel says that use of Actelion's Uptravi may continue

A European Medicines Agency (EMA) drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used amid a probe into five deaths in France among those using the pulmonary arterial hypertension medicine. Shares in the Swiss drugmaker, which is being bought for $30 billion (20 billion pounds) by Johnson & Johnson , rose more than 3 percent by 1340 GMT. Actelion's stock had slipped in late January after France's drug regulator issued a "Dear Doctor" letter recommendi